CCJ

CCJ Stock – A Comprehensive Overview of Market Inference

Now trading at a price of $45.08, Cameco has moved -1.8% so far today.

Cameco returned gains of 107.4% last year, with its stock price reaching a high of $46.76 and a low of $21.22. Over the same period, the stock outperformed the S&P 500 index by 91.2%. More recently, the company's 50-day average price was $41.37. Cameco Corporation provides uranium for the generation of electricity. The mid-cap Basic Materials company is headquartered in Saskatoon, Canada. Cameco has offered a 0.3% dividend yield over the last 12 months.

The Business Has Negative Margins on Average:

2018 2019 2020 2021 2022 2023
Revenue (MM) $2,092 $1,863 $1,800 $1,475 $1,868 $1,868
Revenue Growth n/a -10.94% -3.37% -18.06% 26.65% 0.0%
Operating Margins 3% 5% -4% -9% 1% 1%
Net Margins 8% 4% -1% -7% 5% 5%
Net Income (MM) $166 $74 -$14 -$103 $89 $89
Net Interest Expense (MM) $72 $62 $66 $39 $39 $39
Depreciation & Amort. (MM) $328 $276 $209 $190 $177 $177
Free Cash Flow (MM) $668 $527 $57 $458 $305 $305
Current Ratio 2.38 6.51 6.4 5.18 5.92 5.92
Total Debt (MM) $1,647 $1,092 $1,066 $1,070 $1,183 $1,183
Net Debt / EBITDA 2.35 0.08 1.13 -3.28 0.21 0.21

Cameco's P/B and P/E Ratios Are Higher Than Average:

Cameco has a trailing twelve month P/E ratio of 91.9, compared to an average of 16.53 for the Basic Materials sector. Based on its EPS guidance of $1.09, the company has a forward P/E ratio of 38.0. Furthermore, Cameco is likely overvalued compared to the book value of its equity, since its P/B ratio of 3.2 is higher than the sector average of 2.07.

Cameco Has an Average Rating of Buy:

The 8 analysts following Cameco have set target prices ranging from $43.03 to $55.23 per share, for an average of $50.14 with a buy rating. As of April 2023, the company is trading -17.5% away from its average target price, indicating that there is an analyst consensus of some upside potential.

The largest shareholder is FMR, LLC, whose 6% stake in the company is worth $1,236,028,915.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS